Tag Archives: TCR-T

Strategic Merger of Adaptimmune and TCR2 Tx; Afami-cel’s BLA Filing Completion on Track for Mid-2023; Progress in ADP-A2M4CD8’s Clinical Development; Adaptimmune Q4 2022 Earnings Call Summary

On Monday, March 6, Adaptimmune held its Q4 and FY 2022 earnings call (press release / presentation) highlighting an agreement with TCR2 Tx for merging into a preeminent cell therapy company focused on treating solid tumors (press release). Additionally, management presented updates from afami-cel’s (autologous MAGE-A4 SPEAR-T) BLA filing in synovial sarcoma and ADP-A2M4CD8’s (autologous MAGE-A4 TCR-T) Ph2 SURPASS-3 trial in ovarian cancer. Below, Celltelligence provides insights on the decision of Adaptimmune to partner with TCR2 Tx while discussing the potential of their combined pipeline in the treatment of solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on AstraZeneca’s Cell Therapy Pipeline

On Monday, January 16, AstraZeneca (AZ) announced (press release) the completion of Neogene Therapeutics’ acquisition for developing TCR-T therapies in solid tumors. Moreover, during JPM 2023, AZ introduced (presentation) AZD5851 (GPC3 armored CAR-T), its first official cell therapy program. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in cell therapies, while discussing the potential of its innovative cell therapy pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on AstraZeneca’s Acquisition of Neogene

On Tuesday, November 29, AstraZeneca announced (press release) an agreement to acquire Neogene Therapeutics for the development of TCR-T therapies in solid tumors. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in the cell therapy space, while discussing Neogene’s potential competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on GSK’s Decision to Terminate its Collaboration with Immatics

On Thursday, November 17, Immatics held its Q3 2022 earnings call (press release / presentation) disclosing GSK’s decision to terminate their collaboration to develop novel adoptive cell therapies. Below, Celltelligence provides insights on how GSK’s decision to deprioritize its cell therapy programs could affect Immatics’s strategy, while discussing how BMS could benefit from it.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ICT, Takeda, and PACT Pharma Report Clinical Data in Solid Tumors; SITC 2022 Final Analysis

SITC 2022 Final Analysis: Innovative Cellular Therapeutics (ICT), Takeda, and PACT Pharma presented clinical results from their T cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on GSK’s Decision to Transfer Cell Therapy Programs to Adaptimmune and Terminate Collaboration with Lyell; Is GSK Giving Up on Cell Therapy?

On Tuesday, October 25, Adaptimmune announced (press release / SEC Form 8-K) the transfer of GSK’s NY-ESO and PRAME cell therapy programs to Adaptimmune. Additionally, on Monday, October 24, Lyell Immunopharma reported (SEC Form 8-K) that GSK has terminated its agreement with Lyell for the research and development of T-cell therapies, including LYL132 and LYL331. Below, Celltelligence provides insights on how GSK’s decision could affect the strategy from Adaptimmune and Lyell, while discussing GSK’s uncertain future in cell therapy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

TCR2 Tx Completes Gavo-Cel’s Ph1 Trial; Dosing Started in Gavo-cel’s Pivotal Ph2 Study; Gilead’s KITE-222 Receives Orphan Drug Designation

On Wednesday, September 28, 2022, TCR2 Tx held an investor event highlighting positive topline results from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1 portion of the Ph1/2 trial (press release / presentation). On Tuesday, September 27, Gilead’s (Kite) KITE-222 (autologous CLL-1 CAR-T) was granted Orphan Drug Designation (ODD) by the FDA (FDA Designation). Below, Celltelligence provides insights on gavo-cel’s positive clinical results and future pivotal development as well as discusses KITE-222’s ODD in AML.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

BioNTech Acquires Kite’s TCR-T Platform and Manufacturing Facility; Is Kite Pivoting Away from TCR-Ts?

On Monday, July 19, Gilead (Kite) announced (press release) that BioNTech will acquire Kite’s individualized TCR platform and manufacturing facility in Gaithersburg, MD. Below, Celltelligence provides insights on Gilead’s (Kite) potential approach to treat solid tumors while discussing how BioNTech’s acquisition may quickly advance their pipeline by expanding their US manufacturing footprint.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK and Adaptimmune Present TCR-T Data for Lete-cel and Afami-cel; Novel CAR-Ts for Solid Tumors From Minerva and OriginCell; Will Remodeling the TME With CAR-Ts Improve Solid Tumor Therapies? ASCO 2021 Day 3 Part I

On the third day of ASCO 2021, seven key solid tumor related updates were presented from GSK, Adaptimmune, Minerva, OriginCell Therapeutics, Baylor College / NCI, and UPenn. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Latest Advances Targeting Neoantigens and Developing TCR-T Cell Therapies; Ziopharm Presents Preclinical Data from Their Hotspot TCR-T Library Program; Medigene’s PRAME-Specific TCR PD1-41BB Switch Receptor Could Treat a Broad Range of Liquid and Solid Tumors; AACR 2021 Day 6

On the final day of AACR 2021 Week I, two key TCR-T platform updates were presented from Ziopharm and Medigene, while different approaches for neoantigen discovery and TCR evaluation were explored in a panel discussion. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.